The addition of nivolumab to chemotherapy improves survival in patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. The phase 3 CheckMate 649 trial compared nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for unresectable non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, regardless of PD-ligand 1 (PD-L1) expression. The study, published in The Lancet, ...
New standard of care for hard-to-treat upper GI cancers
By Mardi Chapman
16 Jun 2021